MEDLAB CLINICAL LIMITED (MDC)

The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report.

The securities of the company have been suspended for more than three months. If an entity does not meet the 1 or 2 year deadlines, it will be removed from the official list. The removal will usually take effect from the open of trading on the first trading day after the deadline date.

Shareholders in this company should consider crystallising a capital loss in 2024/25 by selling their shares. This process is now much easier and quicker. It can be achieved online by entering transaction details here. While, this usually makes good economic sense we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person.

The securities of Cann Group Limited were suspended from quotation under Listing Rule 19.11A (b) on Wednesday, 1 March 2024 in relation to the disclaimer conclusion of the independent auditor in its review of CAN's half year financial report for the period ended 31 December 2023. CAN's securities will continue to be suspended under Listing Rule 17.3 until such time that ASX is satisfied with CAN's compliance with the Listing Rules, including Listing Rule 12.2, and that it is otherwise appropriate for CAN's securities to be reinstated to quotation.

The company lodges its Appendix 4D.

The company releases its Quarterly Activities/Appendix 4C Cash Flow Report.

The company releases an addendum.

The company lodges its annual report.

ESV Accounting and Business Advisors have resigned as auditors for Medlab Clinical Limited. The date of resignation was 28 March 2024. The reason for the resignation was ESV not having sufficient resources to meet the time frames required by the company. MNSA Pty Ltd have been appointed as auditors for Medlab. MNSA have provided formal consent to act as statutory auditor of the above-named Company, pursuant to Section 328A of the Corporations Act 2001, subject to ASIC consent.

The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report.

The sale of 100% of the issued share capital in Medlab IP Pty Ltd and Medlab Clinical US Inc., from its wholly owned subsidiary Medlab Pty Ltd to Dr. Sean Hall, completed on Friday, 12 January 2024.

The company lodges its HY23 Interim Report.

The company releases its 2023 EGM Voting Results.

The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report.

The company's general meeting will be held by virtual means www.advancedshare.com.au/virtualmeeting and in person at Hall Chadwick's Melbourne Office, Level 14/440 Collins St, Melbourne Victoria 3000 (Location), on Friday, 22 December 2023 at 1:00pm (AEDT).

The company has today entered into two agreements to implement its proposed restructure. A general meeting will be held in due course to approve resolutions relating to the restructure transaction.

The Company has now paid the ASX annual listing fees and therefore it will not be removed from the Official List because of not paying the ASX annual listing fees. The Company has recently been made aware of an email broadcast circulated by Hall Chadwick regarding expressions of interest for a medical company. The Company wishes to inform Shareholders that this Broadcast is NOT related to Medlab in any manner and confirms that the Broadcast relates to a separate, unrelated entity. The Company has received several indicative bids varying in request, asset, structure, and optionality. The Board has now closed all bidding and has engaged Nova Legal to assist with advising the Company with respect to the legal considerations on the indicative offers. Kerem Kaya (CFO) and Sean Hall (CEO) have agreed with the Board to further reduce their hours to ad-hoc usage whilst maintaining their titles. Both Kerem and Sean's full-time employment contracts have now been terminated, and contractual/employee benefits such as annual leave have been paid out.

Under Listing Rule 17.6, an entity (if not already suspended) that had not paid its annual listing fees by close of business on Monday, 21 August 2023 would have its securities suspended from Official Quotation before the commencement of trading on Tuesday, 22 August 2023. The following entity has failed to pay to ASX Limited the annual listing fees for the year ending 30 June 2024 and consequently will have its securities suspended from quotation immediately. The company has failed to pay to ASX the annual listing fees for the year ending 30 June 2024, and its securities are already suspended from quotation.

The Board anticipates calling an Extraordinary General Meeting (EGM) during September 2023 (or soonest possible date), with details of associated transactions to be included in an Explanatory Memorandum accompanying the Notice of Meeting. It is anticipated that the outcomes from this meeting will conclude the operations of the company.

The Company's Board and Hall Chadwick continue to address significant interest in the Medlab assets. The international marketing campaign is identifying a range of interested parties, with due diligence and negotiations ongoing with various parties. As at the date of this announcement, the Company anticipates a substantive update may be provided in July 2023. Operating costs have been significantly reduced with a small team of part-time employees assisting with pivoting the Company's strategic direction. The Board, remaining staff, and Hall Chadwick are diligently working together on marketing the company, progressing discussions, and additional announcements will be made when appropriate milestones are met.

The company issues a response to ASX Query.

Currently, MDC is operating in a care and maintenance capacity whilst the Board of Directors devise and implement a corporate restructure plan. In order to reduce costs during this phase, the Board retrenched 78% of the workforce whilst retaining nine (9) critical personnel for the purpose of the restructure. The redundancy payments of all terminated staff were processed and paid by MDC on 9 March 2023. Shareholders are advised that the Company is not in any form of a formal insolvency appointment.

Medlab is exploring several possible corporate transactions with the assistance of its external consultants, Hall Chadwick Chartered Accountants. Medlab continues to operate its business, with a focus on addressing the unmet needs of its patients. Stakeholders are assured that the Company is not subject to any form of external control, including that it is not subject to Voluntary Administration.

Hall Chadwick has been engaged as external consultants to assist the current Directors of the Company with an informal workout and restructure of the Company's financial affairs. The Company is currently operating in a care and maintenance capacity whilst the Directors devise and implement a corporate restructure plan. Prior to the suspension, two (2) Directors of the Company have resigned from the Board and in the last week the Company has retrenched 78% of the workforce and is currently operating with skeleton staff for the purpose of the restructure. The business and assets of the Company will be advertised for sale, either via direct acquisition or via proposals from potential joint venture parties. This process is expected to continue for six to eight weeks and updates will be provided periodically. Hall Chadwick has already received and been in discussions with a number of domestic and international parties who are interesting in potential joint venture opportunities.

The securities of Medlab Clinical Limited will be suspended from quotation immediately under Listing Rule 17.3, pending release of an announcement regarding its proposed capital raising. The securities will remain suspended until MDC is in a position to provide a satisfactory announcement to ASX.

listed entity carried for record purposes only